WO2011088331A1 - Stable dosage forms of levomilnacipran - Google Patents

Stable dosage forms of levomilnacipran Download PDF

Info

Publication number
WO2011088331A1
WO2011088331A1 PCT/US2011/021315 US2011021315W WO2011088331A1 WO 2011088331 A1 WO2011088331 A1 WO 2011088331A1 US 2011021315 W US2011021315 W US 2011021315W WO 2011088331 A1 WO2011088331 A1 WO 2011088331A1
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
stable dosage
levomilnacipran
stable
less
Prior art date
Application number
PCT/US2011/021315
Other languages
English (en)
French (fr)
Inventor
Rahul Surana
Murali Divi
Anil Chhettry
Original Assignee
Forest Laboratories Holdings Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/941,293 external-priority patent/US8865937B2/en
Application filed by Forest Laboratories Holdings Limited filed Critical Forest Laboratories Holdings Limited
Priority to JP2012549117A priority Critical patent/JP2013517290A/ja
Priority to EP11733447.4A priority patent/EP2536688A4/de
Priority to CA2790933A priority patent/CA2790933A1/en
Publication of WO2011088331A1 publication Critical patent/WO2011088331A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Definitions

  • the present invention relates to stable dosage formulations of levomilnacipran or a pharmaceutically acceptable salt thereof. Processes for the preparation of these dosage forms and methods of using these dosage forms are also described.
  • Levomilnacipran is the international nonproprietary name for (IS, 2R)-2-(amino methyl)-N,N-diethyl-l -phenyl cyclopropane carboxamide. It is a highly potent selective norepinephrine (NE) and serotonin (5-HT) reuptake inhibitor with greater selectivity for NE reuptake inhibition than for 5-HT reuptake inhibition.
  • NE selective norepinephrine
  • 5-HT serotonin
  • levomilnacipran has an inhibitory selectivity ratio for NE:5-HT of approximately 1.5: 1.
  • levomilnacipran is considered a norepinephrine-serotonin reuptake inhibitor (NSRI) that is pharmacologically distinct from serotonin-norepinephrine reuptake inhibitors (SNRI) having equal or higher inhibitory selectivity for 5-HT than for NE.
  • NSRI norepinephrine-serotonin reuptake inhibitor
  • SNRI serotonin-norepinephrine reuptake inhibitors
  • the improved-stability formulations must achieve a desirable pharmacokinetic profile that is associated with a low incidence of undesirable adverse events (for example, nausea, vomiting and gastric bleeding) in patients.
  • the present invention relates to novel dosage forms of levomilnacipran, as well as processes for preparing these dosage forms and methods for using the dosage forms.
  • the present invention relates to a stable dosage form that comprises levomilnacipran or a pharmaceutically acceptable salt thereof.
  • the present invention relates to a stable dosage form that comprises, or consists essentially of, an active ingredient that comprises substantially pure levomilnacipran or a pharmaceutically acceptable salt thereof. In some embodiments, the present invention relates to a stable dosage form that comprises, or consists essentially of, an active ingredient that comprises at least about 98% by weight (e.g., at least 98% by weight) of levomilnacipran or a pharmaceutically acceptable salt thereof.
  • the present invention relates to a stable dosage form comprising levomilnacipran or a pharmaceutically acceptable salt thereof, wherein the dosage form comprises a X-ray powder diffraction (XRD) pattern that comprises characteristic peaks at 12.0, 20.1 and 22.5 ⁇ 0.2 degrees 20.
  • the XRD pattern also comprises a characteristic peak at 32.7 ⁇ 0.2 degrees 20.
  • the XRD pattern also comprises a characteristic peak at 32.7 ⁇ 0.2 degrees 20.
  • the XRD pattern also comprises a characteristic peak at 6.0 ⁇ 0.2 degrees 20.
  • the present invention relates to a stable dosage form comprising levomilnacipran or a pharmaceutically acceptable salt thereof wherein the dosage form comprises a X-ray powder diffraction (XRD) pattern that comprises characteristic peaks at 6.0, 12.0 and 20.1 ⁇ 0.2 degrees 20.
  • the XRD pattern also comprises a characteristic peak at 22.5 ⁇ 0.2 degrees 20.
  • the present invention relates to a stable dosage form comprising levomilnacipran or a pharmaceutically acceptable salt thereof and about 0.001% to about 0.5% by weight of (IS, 5R) l-phenyl-3-azabicyclo[3-l-0] hexane-2-one.
  • the present invention relates to a stable dosage form comprising levomilnacipran or a pharmaceutically acceptable salt thereof and about 0.001% to about 0.2% by weight of (IS, 5R) l-phenyl-3-azabicyclo[3-l-0] hexane-2-one.
  • the stable dosage form comprises about 45 wt.% to about 60 wt.% an active ingredient comprising substantially pure levomilnacipran or a pharmaceutically acceptable salt thereof.
  • the stable dosage form comprises about 45 wt.% to about 60 wt.% an active ingredient comprising substantially pure levomilnacipran or a pharmaceutically acceptable salt thereof, and about 4 wt.% to about 10 wt.% of a binder.
  • the stable dosage form comprises about 45 wt.% to about 60 wt.% an active ingredient comprising substantially pure levomilnacipran or a pharmaceutically acceptable salt thereof; about 30 wt.% to about 45 wt.% of an inert substrate or filler; and about 4 wt.% to about 10 wt.% of a binder.
  • the stable dosage form comprises about 45 wt.% to about 60 wt.% an active ingredient comprising substantially pure levomilnacipran or a pharmaceutically acceptable salt thereof; about 30 wt.% to about 45 wt.% of an inert substrate or filler; about 4 wt.% to about 10 wt.% of a binder; and about 1 wt.% to about 5 wt.% of an anti-adherent or lubricant.
  • the stable dosage form comprises about 50 wt.% to about 60 wt.% of levomilnacipran or a pharmaceutically acceptable salt thereof; about 30 wt.% to about 40 wt.% of an inert substrate or filler; about 4 wt.% to about 8 wt.% of a binder; and about 1 wt.% to about 5 wt.% of an anti-adherent or lubricant.
  • the stable dosage form comprises about 40%> to about 55% by weight of levomilnacipran or pharmaceutically acceptable salt thereof, about 5% to about 15%) by weight of a release controlling agent, about 25% to about 40%> by weight of an inert substrate, about 3% to about 10%> by weight of a binder, about 3% to about 10% by weight of an anti-adherent, and about 0.1% to about 5% by weight of a plasticizer.
  • the stable dosage form provides a dissolution rate of at least about 80% after about 6 hours to about 16 hours following entry into a use environment.
  • the present invention relates to a stable oral dosage form comprising an active ingredient that comprises between about 10 mg and about 200 mg of levomilnacipran, wherein the dosage form comprises a X-ray powder diffraction (XRD) pattern that comprises characteristic peaks at 12.0, 20.1 and 22.5 ⁇ 0.2 degrees 20.
  • XRD X-ray powder diffraction
  • the present invention relates to an oral dosage form comprising between about 10 mg and about 200 mg of levomilnacipran and about 0.0001% to about 0.5% by weight (e.g., about 0.0001% to about 0.2% by weight or even about 0.0001% to about 0.1% by weight) of (I S, 5R) l-phenyl-3-azabicyclo[3-l-0] hexane-2-one.
  • the present invention relates to an oral dosage form comprising between about 10 mg and about 200 mg of levomilnacipran and about 0.0001% to about 0.5% by weight (e.g., about 0.0001% to about 0.2% by weight or even about 0.0001% to about 0.1% by weight) of (I S, 5R) l-phenyl-3-azabicyclo[3-l-0] hexane-2-one, wherein the dosage form comprises a X-ray powder diffraction (XRD) pattern that comprises characteristic peaks at 12.0, 20.1 and 22.5 ⁇ 0.2 degrees 20.
  • XRD X-ray powder diffraction
  • the dosage form provides a dissolution rate of at least about 80% after about 6 hours to about 16 hours following entry into a use environment.
  • the present invention relates to a stable dosage form comprising levomilnacipran or a pharmaceutically acceptable salt thereof and a release controlling agent, the dosage form sustaining release of the levomilnacipran or pharmaceutically acceptable salt thereof following entry of the dosage form into a use environment.
  • the present invention relates to a stable oral dosage form comprising about 20 mg, about 40 mg, about 80mg or about 120 mg of levomilnacipran or a pharmaceutically acceptable salt thereof.
  • the present invention relates to a method for treating major depressive disorder comprising administering the stable dosage form of levomilnacipran or a pharmaceutically acceptable salt thereof to a patient in need thereof.
  • the present invention relates to a method for treating major depressive disorder with concomitant fatigue comprising administering the stable dosage form of levomilnacipran or a pharmaceutically acceptable salt thereof to a patient in need thereof.
  • the present invention relates to a method for preparing the stable dosage form, wherein the method comprises contacting an inert substrate with levomilnacipran or a pharmaceutically acceptable salt thereof and a dehydrated alcohol.
  • Figure 1 shows the dissolution rates for a stable dosage form of levomilnacipran in accordance with an embodiment of the present invention.
  • Figure 2 show the dissolution rates for a stable dosage form of levomilnacipran in accordance with an embodiment of the present invention following one month of storage at 40°C and 75% relative humidity (RH).
  • Figure 3 show the dissolution rates for a stable dosage form of levomilnacipran in accordance with an embodiment of the present invention following two months of storage at 40°C and 75% RH.
  • Figure 4 show the dissolution rates for a stable dosage form of levomilnacipran in accordance with an embodiment of the present invention following three months of storage at 40°C and 75% RH.
  • Figure 5 show the dissolution rates for a stable dosage form of levomilnacipran in accordance with an embodiment of the present invention following three months of storage at 40°C and 75% RH wherein the dosage form contained 1 gram of desiccant.
  • Figure 6 shows an X-ray powder diffraction pattern (XRD) for an active pharmaceutical ingredient comprising substantially pure levomilnacipran.
  • Figure 7 shows an XRD of a stable immediate-release dosage form of
  • Figure 8 shows an XRD of a stable sustained-release dosage form of
  • Figure 9 shows the mean plasma concentration of levomilnacipran versus time that may be achieved via single administration of Stable dosage forms of levomilnacipran to human patients.
  • Novel stable dosage forms of levomilnacipran, methods of treatment using these dosage forms, and methods for preparing these dosage forms are provided herein.
  • the dosage forms of levomilnacipran have been found to achieve a desirable dissolution profile upon entering a use environment and to have surprisingly high stability. Definitions
  • levomilnacipran refers to (lS,2R)-2-(amino methyl)- N,N-diethyl-l -phenyl cyclopropane carboxamide and pharmaceutically acceptable salts thereof.
  • the term is not inclusive of other isomers of 2-(amino methyl)-N,N-diethyl-l- phenyl cyclopropane carboxamide ⁇ e.g., 1R,2S 2-(amino methyl)-N,N-diethyl-l -phenyl cyclopropane carboxamide) or degradants of (lS,2R)-2-(amino methyl)-N,N-diethyl-l- phenyl cyclopropane carboxamide ⁇ e.g., (IS, 5R) l-phenyl-3-azabicyclo[3-l-0] hexane- 2-one).
  • pharmaceutically acceptable salt refers to any salt of levomilnacipran that is physiologically tolerated by a patient (for example, levomilnacipran
  • substantially pure levomilnacipran is used herein to mean at least 98% by weight of levomilnacipran.
  • an active pharmaceutical ingredient i.e., active ingredient
  • that comprises substantially pure levomilnacipran comprises at least 98%o by weight ⁇ e.g., about 98.5%> by weight) of levomilnacipran and at most 2% by weight of total combined other components (such as other isomers of 2-(amino methyl)- N,N-diethyl-l -phenyl cyclopropane carboxamide and/or degradants of (lS,2R)-2-(amino methyl)-N,N-diethyl-l -phenyl cyclopropane carboxamide).
  • stable when used herein to refer to the dosage form means that the dosage form comprises an active ingredient that comprises substantially pure levomilnacipran.
  • dehydrated alcohol and “dehydrated solvent” are defined herein as they are defined in the U.S. Pharmacopeia to mean an alcohol or solvent that contains less than or equal to 0.8%> by weight of water, which corresponds to less or equal to 99.5% by volume of water.
  • dehydrated solvent is used herein synonymously with the terms “substantially pure solvent,” “anhydrous solvent,” and “absolute solvent”.
  • dehydrated alcohol is used herein synonymously with the terms “substantially pure alcohol,” “anhydrous alcohol,” and “absolute alcohol”.
  • treating is used herein, unless otherwise indicated, to mean to relieve, alleviate, delay, reduce, reverse, improve or prevent at least one symptom of a disease, disorder or condition in a patient which may be treated by inhibition of norepinephrine (NE) and serotonin (5-HT) reuptake.
  • the term “treating” may also mean to arrest, delay the onset (i.e. , the period prior to clinical manifestation of a disease, disorder or condition) and/or reduce the risk of developing or worsening a disease, disease or condition which may be treated by inhibition of norepinephrine (NE) and serotonin (5- HT) reuptake.
  • the term “dosage form” encompasses any oral dosage form or any solid oral dosage form, for example, compositions that are suitable for loading into capsules (e.g., beads, granules, microgranules, or the like), tablets, gelcaps, caplets, lozenges or powders).
  • the dosage form is a dosage form (e.g. , bead, granule, microgranule or the like) that is suited for loading into capsules.
  • the dosage form is an immediate -release dosage form (e.g. , an immediate- release solid dosage form, an immediate-release oral dosage form or an immediate- release solid oral dosage form).
  • the dosage form is an immediate-release composition that is coated with a modified-release (e.g. , sustained-release, delayed-release and/or extended release) composition.
  • the dosage form is a sustained-release dosage form (e.g. , a sustained-release solid dosage form, a sustained-release oral dosage form, or a sustained-release solid oral dosage form).
  • the dosage form is a capsule (e.g., a bead-, granule- or microgranule-filled capsule).
  • the dosage form is a tablet.
  • the dosage form is a once-daily solid oral dosage form.
  • the dosage form is a once- daily capsule.
  • sustained release is used herein, unless otherwise indicated, to refer to dosage forms that release levomilnacipran (and optionally additional active agents contained therein) at a time other than promptly after administration, e.g., over an extended period of time that exceeds the duration of drug release from conventional instant- and immediate-release dosage forms of levomilnacipran.
  • the term "entry into a use environment" is used herein, unless otherwise indicated, to refer to contact of the stable dosage form of levomilnacipran with gastric or intestinal fluid of a patient to whom it is administered, with a fluid intended to simulate gastric or intestinal fluid, or with deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm (for example, with 1000 mL of deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm).
  • dissolution rates define the percentage of levomilnacipran originally contained in an stable dosage form that is released from the dosage form within a specified period of time following entry of the dosage form into a use environment.
  • the terms “effective amount” and “therapeutically effective amount” refer to an amount or quantity of levomilnacipran which is sufficient to elicit an appreciable biological response when administered to a patient.
  • the terms “effective amount” and “therapeutically effective amount” refer to an amount of levomilnacipran (or additional active agent contained in the dosage form) that, when administered to a patient (e.g., human or other mammal) for treating a disease, condition or disorder which may be treated by inhibition of norepinephrine (NE) and serotonin (5-HT) reuptake (e.g., major depressive disorder or anxiety), is sufficient to effect such treatment of one or more symptoms of the disease, disorder or condition, or an amount of levomilnacipran (or additional active agent contained in the dosage form) that is sufficient for inhibition of NE and 5-HT reuptake in a patient.
  • NE norepinephrine
  • 5-HT serotonin
  • the therapeutically effective dosage of levomilnacipran within the stable dosage form for treating depression was found to be between about lOmg and about 150mg of an active ingredient comprising substantially pure levomilnacipran (e.g., between about 20mg and about 120mg of the active ingredient).
  • the dosage form comprises between about 15mg and about 25mg of an active ingredient comprising substantially pure levomilnacipran (e.g., about 20mg).
  • the dosage form comprises between about 35mg and about 45mg of an active ingredient comprising substantially pure levomilnacipran (e.g., about 40mg).
  • the dosage form comprises between about 70 mg and about 90 mg of an active ingredient comprising substantially pure levomilnacipran (e.g., about 80mg). In some embodiments, the dosage form comprises between about lOOmg and about 140mg of an active ingredient comprising substantially pure levomilnacipran (e.g., about 120mg).
  • the term “purity” when used in referring to the stable dosage forms means the degree to which the dosage form is free from (or lacks) specific undesirable components or impurities (for example, degradants or the like).
  • the term “consisting essentially of, when used in reference to the dosage form, means that the dosage form contains no additional active pharmaceutical ingredients but may contain additional inactive components or excipients.
  • “approximately” should be understood to mean within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, “about” can mean within 1 or more than 1 standard deviations, per the practice in the art. Alternatively, “about” can mean a range of up to 20%, preferably up to 10%, more preferably up to 5%, and more preferably still up to 1 % of a given value.
  • the stable dosage form, or the active ingredient contained within the dosage form is crystalline in structure. In some preferred embodiments, the stable dosage form and the active ingredient contained within the dosage form are crystalline in structure. In some embodiments, the stable dosage form has an X-ray powder diffraction pattern (XRD) comprising one or more characteristic peaks as provided in Table 1. In some embodiments, the stable dosage form comprises an active ingredient comprising levomilnacipran wherein the active ingredient has an X- ray powder diffraction pattern (XRD) comprising one or more characteristic peaks as provided in Table 1.
  • XRD X-ray powder diffraction pattern
  • the phrase "one or more peaks” should be understood to be inclusive of (i) stable dosage forms that have XRD peaks at every peak value recited after this phrase, (ii) stable dosage forms that have an XRD peak at only one of the peak values recited after this phrase, as well (iii) stable dosage forms that have XRD peaks at two or more ⁇ e.g. , three or more, four or more, five or more, six or more, or even seven or more) of the peak values recited after this phrase.
  • the stable dosage form of levomilnacipran has an X-ray powder diffraction pattern (XRD) comprising one or more characteristic peaks as provided in Table 2.
  • XRD X-ray powder diffraction pattern
  • the stable dosage form of levomilnacipran is a modified- release dosage form (e.g., a sustain-release dosage form) and has an X-ray powder diffraction pattern (XRD) comprising one or more characteristic peaks as provided in Table 3.
  • XRD X-ray powder diffraction pattern
  • the present invention relates to a stable dosage form comprising levomilnacipran or a pharmaceutically acceptable salt thereof wherein the dosage form comprises a X-ray powder diffraction (XRD) pattern that comprises characteristic peaks at 12.0, 20.1 and 22.5 ⁇ 0.2 degrees 20.
  • the XRD pattern also comprises a characteristic peak at 32.7 ⁇ 0.2 degrees 20.
  • the XRD pattern also comprises a characteristic peak at 32.7 ⁇ 0.2 degrees 20.
  • the XRD pattern also comprises a characteristic peak at 6.0 ⁇ 0.2 degrees 20.
  • the stable dosage form of levomilnacipran has an XRD comprising characteristic peaks at about 6.0, about 12.0 and about 20.1 ⁇ 0.2 degrees 2 ⁇ . In some embodiments, the stable dosage form has an XRD comprising characteristic peaks at about 6.0, about 12.0 and about 22.4 ⁇ 0.2 degrees 2 ⁇ . In some embodiments, the stable dosage form has an XRD comprising characteristic peaks at about 6.0, about 12.0, about 20.1 and about 22.4 ⁇ 0.2 degrees 2 ⁇ . In some embodiments, the stable dosage form has an XRD comprising characteristic peaks at about 6.0, about 20.1 and about 22.4 ⁇ 0.2 degrees 2 ⁇ .
  • the stable dosage form has an XRD comprising characteristic peaks at about 12.0, about 20.1 and about 22.4 ⁇ 0.2 degrees 2 ⁇ . In some embodiments, the stable dosage form has an XRD comprising characteristic peaks at about 6.0 and about 12.0 ⁇ 0.2 degrees 2 ⁇ . In some embodiments, the stable dosage form has an XRD comprising characteristic peaks at about 6.0 and about 20.1 ⁇ 0.2 degrees 2 ⁇ . In some embodiments, the stable dosage form has an XRD comprising characteristic peaks at about 6.0 and about 22.4 ⁇ 0.2 degrees 2 ⁇ .
  • the stable dosage form has an XRD comprising
  • the stable dosage form has an XRD comprising characteristic peaks at about 12.0 and about 22.4 ⁇ 0.2 degrees 2 ⁇ . In some embodiments, the stable dosage form has an XRD comprising characteristic peaks at about 20.1 ⁇ 0.2 degrees 2 ⁇ and at about 22.4 ⁇ 0.2 degrees 2 ⁇ . In some embodiments, the stable dosage form comprises a crystalline form of levomilnacipran having an XRD that comprises characteristic peaks at one or more of about 6.0 ⁇ 0.2 degrees 2 ⁇ , about 12.0 ⁇ 0.2 degrees 2 ⁇ , about 20.1 ⁇ 0.2 degrees 2 ⁇ and about 22.4 ⁇ 0.2 degrees 2 ⁇ .
  • the stable dosage form comprises an active ingredient that comprises substantially pure levomilnacipran wherein the active ingredient comprises one or more of the characteristic peaks shown in Table 1. In some embodiments, the stable dosage form comprises an active ingredient that comprises substantially pure levomilnacipran wherein the stable dosage form comprises one or more of the
  • the stable dosage form and the active ingredient in the dosage form have been found to comprise a surprisingly low concentration of (IS, 5R) l-phenyl-3-azabicyclo[3- 1-0] hexane-2-one, which is represented by Formula (II):
  • the stable dosage form comprises about 0.0001 to about 0.2% by weight of (IS, 5R) l-phenyl-3-azabicyclo[3-l-0] hexane-2-one, as defined by the International Conference on Harmonization (ICH) guidelines, for example after storage for one, two or three months of storage at 40°C and 75% relative humidity.
  • the stable dosage form comprises less than about 0.2%> by weight of (IS, 5R) l-phenyl-3-azabicyclo[3-l-0] hexane-2-one, for example after storage for one, two or three months of storage at 40°C and 75% relative humidity.
  • ICH International Conference on Harmonization
  • the stable dosage form comprises about 0.0001 to about 0.1 % by weight of (IS, 5R) l-phenyl-3-azabicyclo[3-l-0] hexane-2-one, for example, after storage for one, two or three months of storage at 40°C and 75% relative humidity.
  • the stable dosage form comprises about 0.001 to about 0.2 wt.%, about 0.01 to about 0.2 wt.%, about 0.0001 to about 0.15 wt.%, about 0.001 to about 0.15 wt.%, about 0.01 to about 0.15 wt.%, about 0.001 to about 0.1 wt.%, about 0.01 to about 0.1 wt.%, about 0.01 to about 0.08 wt.%, or even about 0.001 to about 0.08 wt.%) of (IS, 5R) l-phenyl-3-azabicyclo[3-l-0] hexane-2-one, for example, after storage for one, two, three, four, five or six months of storage at 40°C and 75% relative humidity.
  • (IS, 5R) l-phenyl-3-azabicyclo[3-l-0] hexane-2-one for example, after storage for one, two, three, four, five or six months of storage at 40°C and 7
  • the stable dosage form comprises about 0.01 to about 0.08 wt.% (e.g., about 0.001 to about 0.08 wt.%) of (IS, 5R) l-phenyl-3- azabicyclo[3-l-0] hexane-2-one, for example, after storage for one, two, three, four, five or six months of storage at 40°C and 75% relative humidity.
  • the stable dosage forms of levomilnacipran can be prepared by any suitable process.
  • the stable dosage forms are prepared by a method comprising contacting an inert substrate or filler with a solution that comprises (or consists essentially of or consists of) levomilnacipran, a solvent (e.g. , a solvent comprising less than 5 wt.%, less than 4 wt.%, less than 3 wt.%, less than 2 wt.%, less than 1 wt.%), less than 0.8 wt.%, less than 0.5 wt.%, or even less than 0.1 wt.% of water) (e.g. , a dehydrated alcohol such as 200-proof ethanol) and optionally a binder and an anti-adherent or lubricant, to form a levomilnacipran composition.
  • a solvent e.g. , a solvent comprising less than 5 wt.%, less than 4 wt.
  • the dosage forms of levomilnacipran are then coated to render them sustained-release dosage forms by contacting the levomilnacipran composition with a solution that comprises a release controlling agent, a solvent (e.g. , a solvent comprising less than 5 wt.%, less than 4 wt.%, less than 3 wt.%, less than 2 wt.%, less than 1 wt.%, less than 0.8 wt.%, less than 0.5 wt.%, or even less than 0.1 wt.% of water) (e.g. , a dehydrated alcohol such as 200-proof ethanol) and optionally a plasticizer, an anti- adherent or glidant.
  • a solvent e.g. , a solvent comprising less than 5 wt.%, less than 4 wt.%, less than 3 wt.%, less than 2 wt.%, less than 1 wt.%, less than 0.8 wt.%,
  • the stable dosage forms are prepared by a method comprising contacting an inert substrate or filler with a solution that comprises levomilnacipran, a solvent (e.g. , a solvent comprising less than 5 wt.%, less than 4 wt.%, less than 3 wt.%, less than 2 wt.%, less than 1 wt.%, less than 0.8 wt.%, less than 0.5 wt.%, or even less than 0.1 wt.% of water), a binder, and an anti-adherent or lubricant, to form a levomilnacipran composition.
  • a solvent e.g. , a solvent comprising less than 5 wt.%, less than 4 wt.%, less than 3 wt.%, less than 2 wt.%, less than 1 wt.%, less than 0.8 wt.%, less than 0.5 wt.%, or even less than 0.1 w
  • the dosage forms of levomilnacipran are then coated to render them sustained-release dosage forms by contacting the levomilnacipran composition with a solution that comprises a release controlling agent, a plasticizer, an anti-adherent or glidant, and a solvent (e.g. , a solvent comprising less than 5 wt.%, less than 4 wt.%, less than 3 wt.%, less than 2 wt.%, less than 1 wt.%), less than 0.8 wt.%, less than 0.5 wt.%, or even less than 0.1 wt.% of water).
  • a solution that comprises a release controlling agent, a plasticizer, an anti-adherent or glidant, and a solvent (e.g. , a solvent comprising less than 5 wt.%, less than 4 wt.%, less than 3 wt.%, less than 2 wt.%, less than 1 wt.%), less
  • the stable dosage forms are prepared by a method comprising contacting an inert substrate or filler with levomilnacipran and optionally a binder, an anti-adherent or lubricant, and/or a solvent (e.g., a solvent comprising less than 5 wt.%), less than 4 wt.%, less than 3 wt.%, less than 2 wt.%, less than 1 wt.%, less than 0.8 wt.%), less than 0.5 wt.%, or even less than 0.1 wt.% of water) to form a solvent (e.g., a solvent comprising less than 5 wt.%), less than 4 wt.%, less than 3 wt.%, less than 2 wt.%, less than 1 wt.%, less than 0.8 wt.%), less than 0.5 wt.%, or even less than 0.1 wt.% of water) to form a solvent (e.g.,
  • levomilnacipran composition e.g., a levomilnacipran core or levomilnacipran beads or granules.
  • the dosage forms of levomilnacipran are then coated to render them sustained-release dosage forms by contacting the levomilnacipran composition with a release controlling agent and optionally a plasticizer, an anti-adherent or lubricant; and/or a solvent (e.g., a solvent comprising less than 5 wt.%, less than 4 wt.%), less than 3 wt.%, less than 2 wt.%, less than 1 wt.%, less than 0.8 wt.%, less than 0.5 wt.%), or even less than 0.1 wt.% of water).
  • a solvent e.g., a solvent comprising less than 5 wt.%, less than 4 wt.%, less than 3 wt.%, less than 2 wt.
  • the stable dosage forms are prepared by a method comprising contacting an inert substrate or filler with a solution that comprises levomilnacipran, a solvent (e.g. , a solvent comprising less than 5 wt.%, less than 4 wt.%, less than 3 wt.%, less than 2 wt.%, less than 1 wt.%, less than 0.8 wt.%, less than 0.5 wt.%, or even less than 0.1 wt.% of water) and optionally a binder and an anti-adherent (or lubricant) to form a levomilnacipran composition (e.g., a core, bead or granule comprising levomilnacipran).
  • a solvent e.g. , a solvent comprising less than 5 wt.%, less than 4 wt.%, less than 3 wt.%, less than 2 wt.%, less than 1 wt
  • the method further comprises coating the levomilnacipran composition with a solution that comprises (or consists essentially of or consists of) a release controlling agent and optionally a plasticizer, an anti-adherent or lubricant; and/or a solvent (e.g., a solvent comprising less than 5 wt.%, less than 4 wt.%, less than 3 wt.%, less than 2 wt.%, less than 1 wt.%, less than 0.8 wt.%, less than 0.5 wt.%, or even less than 0.1 wt.% of water).
  • a solvent e.g., a solvent comprising less than 5 wt.%, less than 4 wt.%, less than 3 wt.%, less than 2 wt.%, less than 1 wt.%, less than 0.8 wt.%, less than 0.5 wt.%, or even less than 0.1 wt.% of water.
  • the stable dosage forms are prepared by a method comprising contacting an inert substrate or filler with a solution comprising
  • the contacting step comprises layering the inert substrate with a drug layering solution that consists essentially of levomilnacipran, a binder, an anti- adherent (or lubricant) and a solvent (e.g.
  • a solvent comprising less than 5 wt.%, less than 4 wt.%, less than 3 wt.%, less than 2 wt.%, less than 1 wt.%, less than 0.8 wt.%, less than 0.5 wt.%, or even less than 0.1 wt.% of water).
  • the contacting step e.g., drug layering step
  • the coating step is performed by a Wurster process (e.g., within a Wurster apparatus) or the like.
  • the combining step and the contacting steps are both performed by a Wurster process or the like.
  • the process for determining the relative percentages of levomilnacipran and other isomers of 2-(amino methyl)-N,N-diethyl-l -phenyl cyclopropane carboxamide (e.g., 1R,2S 2-(amino methyl)-N,N-diethyl-l -phenyl cyclopropane carboxamide) in the active pharmaceutical ingredient can be performed using any suitable method, preferably by reverse phase high performance liquid chromatograph (RP HPLC) (for example, with a UV detection at 220 nm).
  • RP HPLC reverse phase high performance liquid chromatograph
  • the stable dosage form can comprise any therapeutically effective amount of levomilnacipran. In some embodiments, the stable dosage form comprises about 5 to about 200 mg of levomilnacipran. In some embodiments, the stable dosage form comprises about 10 to about 180 mg of levomilnacipran. In some embodiments, the stable dosage form comprises about 20 to about 150 mg of levomilnacipran. In some embodiments, the stable dosage form comprises about 20 to about 120 mg of levomilnacipran.
  • the stable dosage form can comprise about 20 mg, about 40 mg, about 50 mg, about 60 mg, about 80 mg, about 100 mg, 120 mg, or about 240 mg of levomilnacipran.
  • the stable dosage form can comprise any suitable weight percentage of levomilnacipran relative to other components of the dosage form.
  • the stable dosage form can comprise about 35 to about 65% by weight (e.g., about 35 to about 60 wt.%, about 35 to about 55 wt.%, about 40 to about 55 wt.%, or about 40 to about 50 wt.%) of levomilnacipran.
  • the stable dosage form of levomilnacipran also comprises an inert substrate or filler.
  • the stable dosage form comprises an inert substrate that comprises sugar for example sucrose (e.g., sugar spheres).
  • suitable inert substrates or fillers include, for example, isomalt, dicalcium phosphate dihydrate, calcium sulfate, lactose, mannitol, sorbitol, cellulose, microcrystalline cellulose, kaolin, sodium chloride, dry starch, hydrolyzed starches, pre-gelatinized starch, silicone dioxide, titanium oxide, magnesium aluminum silicate, or a mixture thereof.
  • the stable dosage form can comprise any suitable amount of the inert substrate or filler (e.g., sugar spheres). In some embodiments, the stable dosage form comprises about 15 to about 45% by weight of the inert substrate or filler. In some embodiments, the stable dosage form comprises about 20 to about 40 wt.% of the inert substrate or filler. In some embodiments, the stable dosage form comprises about 25 to about 40 wt.% of the inert substrate or filler. In some embodiments, the stable dosage form comprises about 30 to about 40 wt.% of the inert substrate or filler In some embodiments, the stable dosage form comprises about 35 to about 40 wt.% of the inert substrate or filler.
  • the stable dosage form comprises about 15 to about 45% by weight of the inert substrate or filler. In some embodiments, the stable dosage form comprises about 20 to about 40 wt.% of the inert substrate or filler. In some embodiments, the stable dosage form comprises about 25 to about 40 wt.% of the in
  • the stable dosage form can comprise sugar spheres in any suitable size.
  • the stable dosage form comprises sugar spheres having a size of about 20 to about 50 mesh.
  • the stable dosage form comprises sugar spheres having a size of approximately about 25 to about 45 mesh.
  • the stable dosage form comprises sugar spheres having a size of about 25 to about 40 mesh.
  • the stable dosage form comprises sugar spheres having a size of approximately about 30 to about 40 mesh (for example, about 30 to about 35 mesh).
  • the stable dosage form may comprise about 30 to about 40 wt.% (e.g., about 35 to about 40 wt.%) of sugar spheres having a size of about 30 to about 40 mesh.
  • the stable dosage form also comprises a binder in some preferred embodiments, for example polyvinyl pyrrolidone (e.g., Povidone K30).
  • a binder in some preferred embodiments, for example polyvinyl pyrrolidone (e.g., Povidone K30).
  • suitable binders include, for example, starch, polyvinyl alcohol, pre-gelatinized starch, gelatin, sucrose, glucose, dextrose, lactose, sorbitol, polyethylene glycol, waxes, natural and synthetic gums such as acacia, tragacanth, sodium alginate, hydroxypropylmethylcellulose,
  • hydroxypropylcellulose, ethylcellulose, veegum, and synthetic polymers such as acrylic acid and methacrylic acid copolymers, methacrylic acid copolymers, methyl methacrylate copolymers, aminoalkyl methacrylate copolymers, polyacrylic acid/polymethacrylic acid, or a mixture thereof.
  • the stable dosage form can comprise any suitable amount of the binder (e.g., PVP). In some embodiments, the stable dosage form comprises about 0.1 to about 15% by weight of a binder. In some embodiments, the stable dosage form comprises about 1 to about 12% by weight of a binder. In some embodiments, the stable dosage form comprises about 1 to about 10%> by weight of a binder. In some embodiments, the stable dosage form comprises about 2 to about 10%> by weight of a binder.
  • the binder e.g., PVP
  • the stable dosage form comprises about 0.1 to about 15% by weight of a binder. In some embodiments, the stable dosage form comprises about 1 to about 12% by weight of a binder. In some embodiments, the stable dosage form comprises about 1 to about 10%> by weight of a binder. In some embodiments, the stable dosage form comprises about 2 to about 10%> by weight of a binder.
  • the stable dosage form comprises about 3 to about 10%) by weight of a binder (e.g., PVP). In some embodiments, the stable dosage form comprises about 4 to about 10% by weight of the binder. In some embodiments, the stable dosage form comprises about 2 to about 8% by weight of the binder. In some embodiments, the stable dosage form comprises about 4 to about 8% by weight of the binder. In some embodiments, the stable dosage form comprises about 5 to about 7% by weight of the binder.
  • a binder e.g., PVP
  • the stable dosage form comprises about 4 to about 10% by weight of the binder. In some embodiments, the stable dosage form comprises about 2 to about 8% by weight of the binder. In some embodiments, the stable dosage form comprises about 4 to about 8% by weight of the binder. In some embodiments, the stable dosage form comprises about 5 to about 7% by weight of the binder.
  • the stable dosage form also comprises an anti-adherent or lubricant in some preferred embodiments, for example, talc.
  • an anti-adherent or lubricant in some preferred embodiments, for example, talc.
  • suitable anti-adherents or lubricants include, for example, magnesium stearate, calcium stearate, stearic acid, glycerol behenate, polyethylene glycol, talc, mineral oil, sodium stearyl fumarate or mixtures thereof.
  • the stable dosage form can comprise any suitable amount of the lubricant or anti- adherent (for example, talc). In some embodiments, the stable dosage form comprises about 0.1 to about 15% by weight of the lubricant or anti-adherent. In some
  • the stable dosage form comprises about 1 to about 12% by weight of the lubricant or anti-adherent. In some embodiments, the stable dosage form comprises about 2 to about 10% by weight of the lubricant or anti-adherent. In some embodiments, the stable dosage form comprises about 3 to about 10% by weight of the lubricant or anti- adherent. In some embodiments, the stable dosage form comprises about 4 to about 10% by weight of the lubricant or anti-adherent. In some embodiments, the stable dosage form comprises about 4 to about 8% by weight of the lubricant or anti-adherent. In some embodiments, the stable dosage form comprises about 5 to about 8% by weight of the lubricant or anti-adherent.
  • the stable dosage form comprises about 4 to about 7.5% by weight of the lubricant or anti-adherent. In some preferred embodiments, the stable dosage form comprises about 5 to about 7% by weight of the lubricant or anti- adherent.
  • the stable dosage form is a sustained-release (SR) dosage form and comprises a release controlling agent, polymeric agent or coating polymer (e.g. , ethyl cellulose) which substantially contributes to sustaining the release of
  • SR sustained-release
  • release controlling agents include, for example, a cellulose and cellulose derivative, wax, carbomer, polyalkylene polyol, polycarbophil, methacrylic acid derivative, gelatin, gum, polyethylene oxide, and polyvinyl pyrrolidone, or mixtures thereof.
  • the release controlling agent, polymeric additive or coating polymer is selected from ethyl cellulose,
  • acrylic acid polymers and copolymers preferably formed from acrylic acid, methacrylic acid, methyl acrylate, ethyl acrylate, methyl methacrylate and/or ethyl methacrylate), and other methacrylic resins that are commercially available under the trade name EudragitTM (Rohm Pharma; Westerstadt, Germany), including EudragitTM L30D-55 and LI 00-55, EudragitTM, EudragitTM and EudragitTM NE, RL and RS; vinyl polymers and copolymers such as polyvinyl pyrrolidone, vinyl acetate, vinyl acetate phthalate, vinyl acetate crotonic acid copolymer, and ethylene-vinyl acetate copolymer; enzymatically degradable polymers such as azo polymers, pectin, chitosan, amylose and guar gum; zein and shellac, or mixtures thereof.
  • the stable dosage form can comprise any suitable amount of the release controlling agent, polymeric agent or coating polymer (e.g., ethyl cellulose).
  • the stable dosage form preferably comprises about 5 to about 15% by weight of the release controlling agent, polymeric agent or coating polymer. However, n some embodiments, the stable dosage form comprises about 2 to about 20% by weight of a release controlling agent, polymeric agent or coating polymer. In some embodiments, the stable dosage form comprises about 5 to about 12% by weight of a release controlling agent, polymeric agent or coating polymer. In some embodiments, the stable dosage form comprises about 8 to about 12% by weight of a release controlling agent, polymeric agent or coating polymer.
  • the stable dosage form comprises about 8 to about 1 1% by weight of a release controlling agent, polymeric agent or coating polymer. In some embodiments, the stable dosage form comprises about 8 to about 10%> by weight of a release controlling agent, polymeric agent or coating polymer.
  • the stable dosage form also comprises a plasticizer in some preferred embodiment
  • triethyl citrate for example triethyl citrate.
  • suitable plasticizers include, for example, polyethylene glycol, propylene glycol, triacetin, dimethyl phthalate, diethyl phthalate, dibutyl phthalate, dibutyl sebacate, tributyl citrate, triethyl acetyl citrate, glycerol monostearate, castor oil, acetylated monoglycerides, or a mixture thereof.
  • the stable dosage form can comprise any suitable amount of the plasticizer (for example, triethyl citrate). In some embodiments, the stable dosage form comprises about 0.1 to about 10%) by weight of the plasticizer. In some embodiments, the stable dosage form comprises about 0.5 to about 8% by weight of the plasticizer. In some
  • the stable dosage form comprises about 0.5 to about 5% by weight of the plasticizer. In some embodiments, the stable dosage form comprises about 1 to about 5% by weight of the plasticizer. In some embodiments, the stable dosage form comprises about 1 to about 3% by weight of the plasticizer.
  • the stable dosage form of levomilnacipran can comprise any additional excipients or additives in some embodiments, such as plasticizers, pigments, colorants, stabilizing agents, glidants, or the like.
  • the dosage form comprises about 30 wt.% to about 65 wt.%) (e.g., about 40 wt.% to about 60 wt.%, about 45 wt.% to about 60 wt.% or even about 50 wt.% to about 60 wt.%) of levomilnacipran (or an active ingredient comprising at least 98% by weight or even substantially pure levomilnacipran); about 25 wt.%) to about 55 wt.% (e.g., about 30 wt.% to about 45 wt.% or even about 30 wt.% to about 40 wt.%) of an inert substrate or filler; about 2 wt.% to about 12 wt.% (e.g.,
  • the dosage form comprises about 45 wt.% to about 60 wt.% of levomilnacipran (or an active ingredient comprising at least 98% by weight or even substantially pure levomilnacipran); about 30 wt.% to about 45 wt.% of an inert substrate or filler; about 4 wt.% to about 10 wt.% of a binder; and about 1 wt.% to about 5 wt.% of an anti-adherent or lubricant.
  • the dosage form comprises about 50 wt.% to about 60 wt.% of levomilnacipran (or an active ingredient comprising at least 98% by weight or even substantially pure levomilnacipran); about 30 wt.% to about 40 wt.% of an inert substrate or filler; about 4 wt.% to about 8 wt.% of a binder; and about 1 wt.% to about 5 wt.% of an anti-adherent or lubricant.
  • the stable dosage form comprises 40 to about 55 wt.%) (e.g., about 40 to about 50 wt.%) of levomilnacipran; about 3 to about 10 wt.% (e.g., about 4 to about 8 wt.%) of a binder (e.g., PVP); and about 0.1 to about 4 wt.% (e.g., about 1 to about 3 wt.%) of a plasticizer (e.g., triethyl citrate).
  • a binder e.g., PVP
  • a plasticizer e.g., triethyl citrate
  • the stable dosage form comprises 40 to about 55 wt.%) (e.g., about 40 to about 50 wt.%) of levomilnacipran; about 3 to about 7 wt.% (e.g., about 4 to about 7 wt.%) of an anti-adherent or lubricant (for example, talc); and about 0.1 to about 4 wt.% (e.g., about 1 to about 3 wt.%) of a plasticizer (e.g., triethyl citrate).
  • levomilnacipran for example, talc
  • an anti-adherent or lubricant for example, talc
  • a plasticizer e.g., triethyl citrate
  • the stable dosage form comprises 40 to about 55 wt.% (e.g., about 40 to about 50 wt.%) of levomilnacipran; about 3 to about 10 wt.% (e.g., about 4 to about 8 wt.%) of a binder (e.g., PVP); about 3 to about 7 wt.% (e.g., about 4 to about 7 wt.%) of an anti-adherent or lubricant (for example, talc); and about 0.1 to about 4 wt.% (e.g., about 1 to about 3 wt.%) of a plasticizer (e.g., triethyl citrate).
  • a binder e.g., PVP
  • an anti-adherent or lubricant for example, talc
  • a plasticizer e.g., triethyl citrate
  • the stable dosage form comprises 40 to about 55 wt.%) (e.g., about 40 to about 50 wt.%) of levomilnacipran; about 3 to about 10 wt.% (e.g., about 4 to about 8 wt.%) of a binder (e.g., PVP); and about 5-10.5%) by weight (e.g., about 6 to about 10 wt.%) of a release controlling agent (for example, ethyl cellulose).
  • a binder e.g., PVP
  • a release controlling agent for example, ethyl cellulose
  • the stable dosage form comprises 40 to about 55 wt.%) (e.g., about 40 to about 50 wt.%) of levomilnacipran; about 3 to about 7 wt.% (e.g., about 4 to about 7 wt.%) of an anti-adherent or lubricant (for example, talc); and about 5- 10.5%) by weight (e.g., about 6 to about 10 wt.%) of a release controlling agent (for example, ethyl cellulose).
  • levomilnacipran for example, levomilnacipran
  • about 3 to about 7 wt.% e.g., about 4 to about 7 wt.%
  • an anti-adherent or lubricant for example, talc
  • a release controlling agent for example, ethyl cellulose
  • the stable dosage form comprises 40 to about 55 wt.%) (e.g., about 40 to about 50 wt.%) of levomilnacipran; about 3 to about 10 wt.% (e.g., about 4 to about 8 wt.%) of a binder (e.g., PVP); about 5-10.5%) by weight (e.g., about 6 to about 10 wt.%) of a release controlling agent (for example, ethyl cellulose); and about 5-10.5%) by weight (e.g., about 6 to about 10 wt.%) of a release controlling agent (for example, ethyl cellulose).
  • a binder e.g., PVP
  • a release controlling agent for example, ethyl cellulose
  • a release controlling agent for example, ethyl cellulose
  • the stable dosage form comprises 40 to about 55 wt.%) (e.g., about 40 to about 50 wt.%) of levomilnacipran; about 3 to about 7 wt.% (e.g., about 4 to about 7 wt.%) of an anti-adherent or lubricant (for example, talc); about 5- 10.5%) by weight (e.g., about 6 to about 10 wt.%) of a release controlling agent (for example, ethyl cellulose); and about 5-10.5%) by weight (e.g., about 6 to about 10 wt.%) of a release controlling agent (for example, ethyl cellulose).
  • the stable dosage form comprises about 35 to about 60% by weight (e.g., about 35 to about 55 wt.% or about 40 to about 55 wt.%) of levomilnacipran; about 20 to about 45% by weight (e.g., about 20 to about 40 wt.%, about 25 to about 40 wt.% or about 25 to 35 wt.%) of an inert substrate or filler (e.g., sugar spheres); about 1 to about 15% by weight (e.g., about 2 to about 12 wt.%, about 3 to about 10 wt.%), about 3 to about 9 wt.% or about 4 to about 8 wt.%) of a binder (for example, PVP); about 1 to about 15% by weight (e.g., about 2 to about 12 wt.%, about 3 to about 10 wt.%), about 3 to about 9 wt.%, about 4 to about 8 wt.% or about 4 to about 7 wt.%)
  • the stable dosage form comprises about 35 to about 60%) by weight (e.g., about 35 to about 55 wt.% or about 40 to about 55 wt.%) of levomilnacipran; about 20 to about 45% by weight (e.g., about 20 to about 40 wt.%, about 25 to about 40 wt.% or about 25 to 35 wt.%) of an inert substrate (e.g., sugar substrate) (e.g., about 30-35 mesh sugar spheres); about 1 to about 15% by weight (e.g., about 2 to about 12 wt.%, about 3 to about 10 wt.%, about 3 to about 9 wt.% or about 4 to about 8 wt.%) of PVP (e.g., Povidone K30); about 1 to about 15% by weight (e.g., about 2 to about 12 wt.%, about 3 to about 10 wt.%, about 3 to about 9 wt.%, about 3 to about 8 w
  • PVP
  • the stable dosage form comprises 40 to about 55 wt.%) (e.g., about 40 to about 50 wt.%) of levomilnacipran; about 25 to about 40 wt.% of sugar spheres (e.g., about 30-35 mesh sugar spheres); about 2 to about 10 wt.% (e.g., about 4 to about 8 wt.%) of PVP (e.g., Povidone K30); about 2 to about 10 wt.% (e.g., about 4 to about 8 wt.%) of talc; about 5 to about 15 wt.% of ethyl cellulose; about 0.1 to about 5 wt.% (e.g., about 1 to about 5 wt.%) of triethyl citrate.
  • PVP e.g., Povidone K30
  • the stable dosage forms can comprise beads or granules (e.g., microgranules or other like core) of levomilnacipran that are coated with release controlling agent in any suitable thickness to achieve a desired pK profile.
  • the stable dosage form is a capsule that contains beads or granules (or similar core), wherein the beads or granules (or similar core) are coated with a coating composition comprising a release controlling agent (and optionally a plasticizer, anti-adherent or lubricant, and/or a solvent) having any desired average thickness.
  • the coating composition can be applied to the beads or granules (or similar core) with an average thickness of about 1 to about 100 microns (e.g., about 5 to about 75 microns, about 5 to about 60 microns, about 5 to about 50 microns, about 5 to about 40 microns, about 5 to about 30 microns, about 10 to about 30 microns, about 15 to about 30 microns, about 20 to about 30 microns, about 25 to about 35 microns, or even about 25 to about 35 microns).
  • microns e.g., about 5 to about 75 microns, about 5 to about 60 microns, about 5 to about 50 microns, about 5 to about 40 microns, about 5 to about 30 microns, about 10 to about 30 microns, about 15 to about 30 microns, about 20 to about 30 microns, about 25 to about 35 microns, or even about 25 to about 35 microns.
  • the stable dosage form comprises coated beads or granules (or similar core) of levomilnacipran wherein the coating comprises one or more release controlling agents (e.g., ethyl cellulose) and wherein the average thickness of the coating on the beads or granules (or similar core) is about 20 to about 35 microns (e.g., about 20 to about 30 microns).
  • the coating comprises one or more release controlling agents (e.g., ethyl cellulose) and wherein the average thickness of the coating on the beads or granules (or similar core) is about 20 to about 35 microns (e.g., about 20 to about 30 microns).
  • the dosage form can be a bead-, granule- or microgranule-filled capsule wherein the beads, granules or microgranules (or similar core) are coated with a coating composition (e.g., comprising ethyl cellulose) at an average thickness of about 20 to about 30 microns (e.g.,
  • the stable dosage form is in the form of beads or granules
  • the stable dosage form is in the form of beads or granules (e.g., coated beads or granules) which have an average diameter of about 400 to about 900 microns.
  • the stable dosage form is in the form of beads or granules (e.g., coated beads or granules) which have an average diameter of about 500 to about 800 microns.
  • the stable dosage form is in the form of beads or granules (e.g., coated beads or granules) which have an average diameter of about 600 to about 800 microns.
  • the stable dosage form is in the form of beads or granules (e.g., coated beads or granules) which have an average diameter of about 600 to about 750 microns.
  • the stable dosage form is in the form of beads or granules (e.g., coated beads or granules) which have an average diameter of about 650 to about 850 microns. In some embodiments, the stable dosage form is in the form of beads or granules (e.g., coated beads or granules) which have an average diameter of less than about 1000 microns. In some embodiments, the stable dosage form is in the form of beads or granules (e.g., coated beads or granules) which have an average diameter of less than about 900 microns.
  • the invention also provides a method for using the stable dosage form of levomilnacipran in the manufacture of a medicament for the treatment of a disorder that can be managed by inhibition of 5-HT and NE reuptake, for example, anxiety disorders or depression (e.g., major depressive disorder).
  • a disorder that can be managed by inhibition of 5-HT and NE reuptake, for example, anxiety disorders or depression (e.g., major depressive disorder).
  • the stable dosage form is loaded into a capsule (e.g., an
  • the stable dosage form is loaded into an HPMC capsule.
  • Such an HPMC capsule can then be packaged in bottles or canisters with or without a desiccant (e.g., about 0.01 to about 2 grams, about 0.01 to about 1 gram or even about 0.01 to about 0.8 grams of desiccant).
  • the stable dosage form is contained within HPMC capsules and packaged without a desiccant.
  • the stable dosage form is contained within HPMC capsules and packaged with a desiccant.
  • the stable dosage form is contained within gelatin capsules and packaged without a desiccant.
  • the stable dosage form is contained within gelatin capsules and packaged with a desiccant.. Dissolution Rate of the stable dosage forms
  • the stable dosage forms of levomilnacipran have been found to provide desirable dissolution rates following entry into a use environment.
  • the stable dosage form provides a dissolution rate (e.g., a single phase dissolution rate) of at least about 80% (e.g., at least 80%>) after about 6 hours to about 16 hours following entry into a use environment.
  • the stable dosage form provides a dissolution rate of at least about 80% after about 6 hours to about 12 hours following entry into a use environment.
  • the stable dosage form provides a dissolution rate (e.g. , a single phase dissolution rate) of less than about 60%> after about 2 hours following entry into a use environment. In some embodiments, the stable dosage form provides a dissolution rate (e.g., a single phase dissolution rate) of less than about 55% after about 2 hours following entry into a use environment. In some embodiments, the stable dosage form provides a dissolution rate of less than about 50% after about 2 hours following entry into a use environment. In some embodiments, the stable dosage form provides a dissolution rate of less than about 45% after about 2 hours following entry into a use environment. In some embodiments, the stable dosage form provides a dissolution rate of less than about 40% after about 2 hours following entry into a use environment.
  • a dissolution rate e.g. , a single phase dissolution rate
  • the stable dosage form provides a dissolution rate of about 20%> to about 60% after about 2 hours following entry into a use environment. In some embodiments, the stable dosage form provides a dissolution rate of about 25% to about 55% after about 2 hours following entry into a use environment. In some embodiments, the stable dosage form provides a dissolution rate of about 30%> to about 50%> after about 2 hours following entry into a use environment. In some embodiments, the stable dosage form provides a dissolution rate (e.g., a single phase dissolution rate) of less than about 90%> after about 4 hours following entry into a use environment. In some embodiments, the stable dosage form provides a dissolution rate of less than about 80% after about 4 hours following entry into a use environment.
  • a dissolution rate e.g., a single phase dissolution rate
  • the stable dosage form provides a dissolution rate of less than about 70% after about 4 hours following entry into a use environment. In some embodiments, the stable dosage form provides a dissolution rate of less than about 65% after about 4 hours following entry into a use environment. In some embodiments, the stable dosage form provides a dissolution rate of less than about 60%> after about 4 hours following entry into a use environment. In some embodiments, the stable dosage form provides a dissolution rate of about 40%> to about 80%> after about 4 hours following entry into a use environment. In some embodiments, the stable dosage form provides a dissolution rate of about 45% to about 75% after about 4 hours following entry into a use environment. In some embodiments, the stable dosage form provides a dissolution rate of about 40% to about 70% after about 4 hours following entry into a use environment.
  • the stable dosage form provides a dissolution rate (e.g. , a single phase dissolution rate) of less than about 90%> after about 6 hours following entry into a use environment. In some embodiments, the stable dosage form provides a dissolution rate of less than about 85% after about 6 hours following entry into a use environment. In some embodiments, the stable dosage form provides a dissolution rate of less than about 80% after about 6 hours following entry into a use environment. In some embodiments, the stable dosage form provides a dissolution rate of less than about 75% after about 6 hours following entry into a use environment. In some embodiments, the stable dosage form provides a dissolution rate of less than about 70%> after about 6 hours following entry into a use environment.
  • a dissolution rate e.g. , a single phase dissolution rate
  • the stable dosage form provides a dissolution rate of about 40%> to about 95% after about 6 hours following entry into a use environment. In some embodiments, the stable dosage form provides a dissolution rate of about 50%> to about 90%> after about 6 hours following entry into a use environment. In some embodiments, the stable dosage form provides a dissolution rate of about 60% to about 85% after about 6 hours following entry into a use environment. In some embodiments, the stable dosage form provides a dissolution rate of about 60%> to about 80% after about 6 hours following entry into a use environment.
  • the stable dosage form provides a dissolution rate (e.g. , a single phase dissolution rate) of less than about 95% after about 8 hours following entry into a use environment. In some embodiments, the stable dosage form provides a dissolution rate of less than about 90% after about 8 hours following entry into a use environment. In some embodiments, the stable dosage form provides a dissolution rate of less than about 85% after about 8 hours following entry into a use environment. In some embodiments, the stable dosage form provides a dissolution rate of about 65%> to about 95% after about 8 hours following entry into a use environment. In some embodiments, the stable dosage form provides a dissolution rate of about 65 % to about 90% after about 8 hours following entry into a use environment.
  • a dissolution rate e.g. , a single phase dissolution rate
  • the stable dosage form provides a dissolution rate of about 65%> to about 85% after about 8 hours following entry into a use environment. In some embodiments, the stable dosage form provides a dissolution rate of about 70%> to about 85% after about 8 hours following entry into a use environment. In some embodiments, the stable dosage form provides a dissolution rate of about 70%> to about 80%> after about 8 hours following entry into a use environment.
  • the stable dosage form provides a dissolution rate (e.g. , a single phase dissolution rate) of less than about 95% after about 12 hours following entry into a use environment. In some embodiments, the stable dosage form provides a dissolution rate of less than about 90% after about 12 hours following entry into a use environment. In some embodiments, the stable dosage form provides a dissolution rate of about 75% to about 95% after about 12 hours following entry into a use environment. In some embodiments, the stable dosage form provides a dissolution rate of about 80% to about 95% after about 12 hours following entry into a use environment. In some embodiments, the stable dosage form provides a dissolution rate of about 80% to about 90% after about 12 hours following entry into a use environment.
  • a dissolution rate e.g. , a single phase dissolution rate
  • the stable dosage form provides a dissolution rate (e.g., a single phase dissolution rate) of at least about 80% (e.g., at least 80%) after about 6 hours to about 16 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm (for example, after entry into 1000 mL of deionized water at a temperature of 37°C and subjected to USP apparatus II at 75 rpm, wherein levomilnacipran is quantified using HPLC with a UV detector at a wavelength of 220 nm).
  • the stable dosage form provides a dissolution rate of at least about 80% after about 6 hours to about 12 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm.
  • the stable dosage form provides a dissolution rate (e.g. , a single phase dissolution rate) of less than about 60%> after about 2 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm. In some embodiments, the stable dosage form provides a dissolution rate (e.g. , a single phase dissolution rate) of less than about 55% after about 2 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm.
  • a dissolution rate e.g. , a single phase dissolution rate
  • the stable dosage form provides a dissolution rate of less than about 50% after about 2 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm. In some embodiments, the stable dosage form provides a dissolution rate of less than about 45% after about 2 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm. In some embodiments, the stable dosage form provides a dissolution rate of less than about 40% after about 2 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm.
  • the stable dosage form provides a dissolution rate of about 20% to about 60% after about 2 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm. In some embodiments, the stable dosage form provides a dissolution rate of about 25% to about 55% after about 2 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm. In some embodiments, the stable dosage form provides a dissolution rate of about 30% to about 50% after about 2 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm.
  • the stable dosage form provides a dissolution rate (e.g., a single phase dissolution rate) of less than about 90% after about 4 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm. In some embodiments, the stable dosage form provides a dissolution rate of less than about 80% after about 4 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm. In some embodiments, the stable dosage form provides a dissolution rate of less than about 70% after about 4 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm.
  • a dissolution rate e.g., a single phase dissolution rate
  • the stable dosage form provides a dissolution rate of less than about 65% after about 4 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm. In some embodiments, the stable dosage form provides a dissolution rate of less than about 60% after about 4 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm. In some embodiments, the stable dosage form provides a dissolution rate of about 40%> to about 80%> after about 4 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm.
  • the stable dosage form provides a dissolution rate of about 45% to about 75% after about 4 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm. In some embodiments, the stable dosage form provides a dissolution rate of about 40% to about 70% after about 4 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm.
  • the stable dosage form provides a dissolution rate (e.g. , a single phase dissolution rate) of less than about 90%> after about 6 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm. In some embodiments, the stable dosage form provides a dissolution rate of less than about 85% after about 6 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm. In some embodiments, the stable dosage form provides a dissolution rate of less than about 80%> after about 6 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm.
  • a dissolution rate e.g. , a single phase dissolution rate
  • the stable dosage form provides a dissolution rate of less than about 75% after about 6 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm. In some embodiments, the stable dosage form provides a dissolution rate of less than about 70% after about 6 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm. In some embodiments, the stable dosage form provides a dissolution rate of about 40% to about 95% after about 6 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm.
  • the stable dosage form provides a dissolution rate of about 50% to about 90% after about 6 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm. In some embodiments, the stable dosage form provides a dissolution rate of about 60% to about 85% after about 6 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm. In some embodiments, the stable dosage form provides a dissolution rate of about 60%> to about 80% after about 6 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm.
  • the stable dosage form provides a dissolution rate (e.g. , a single phase dissolution rate) of less than about 95% after about 8 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm. In some embodiments, the stable dosage form provides a dissolution rate of less than about 90% after about 8 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm. In some embodiments, the stable dosage form provides a dissolution rate of less than about 85% after about 8 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm.
  • a dissolution rate e.g. , a single phase dissolution rate
  • the stable dosage form provides a dissolution rate of about 65% to about 95% after about 8 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm. In some embodiments, the stable dosage form provides a dissolution rate of about 65% to about 90% after about 8 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm. In some embodiments, the stable dosage form provides a dissolution rate of about 65 % to about 85% after about 8 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm.
  • the stable dosage form provides a dissolution rate of about 70% to about 85% after about 8 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm. In some embodiments, the stable dosage form provides a dissolution rate of about 70% to about 80% after about 8 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm.
  • the stable dosage form provides a dissolution rate (e.g. , a single phase dissolution rate) of less than about 95% after about 12 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm. In some embodiments, the stable dosage form provides a dissolution rate of less than about 90% after about 12 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm. In some embodiments, the stable dosage form provides a dissolution rate of about 75% to about 95% after about 12 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm.
  • a dissolution rate e.g. , a single phase dissolution rate
  • the stable dosage form provides a dissolution rate of about 80% to about 95% after about 12 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm. In some embodiments, the stable dosage form provides a dissolution rate of about 80% to about 90% after about 12 hours following entry into deionized water at a temperature of about 37°C and subjected to USP apparatus II at 75 rpm.
  • the stable dosage form of levomilnacipran achieves the discussed dissolution rates after storage of the dosage form for one, two, or even three months at 40°C and 75% relative humidity (RH).
  • the stable dosage forms provide sustained release of levomilnacipran over an extended period of time upon entering a use environment and are expected to achieve a desirable pK profile upon administration to human patients.
  • the stable dosage forms may provide (i.e., are expected to achieve) a therapeutic blood plasma level of levomilnacipran over approximately a twenty-four hour period, for example after single administration.
  • the stable dosage forms may release levomilnacipran for about 4 hours to about 24 hours (e.g., for about 5 to about 24 hours, or even for about 6 hours to about 24 hours) following entry of the dosage form into a use environment.
  • the stable dosage form may provide a mean Tmax
  • the stable dosage form may provide a mean Tmax (average time to maximum plasma
  • the stable dosage form may provide a mean Tmax (average time to maximum plasma concentration) of at least 3 hours following administration (e.g., single administration) to a patient.
  • the stable dosage form may provide a mean Tmax of at least 3.5 hours.
  • the stable dosage form of the present invention may provide a mean Tmax of at least 4 hours.
  • the stable dosage form may provide a mean Tmax of at least 4.5 hours.
  • the dosage form may provide a mean Tmax of at least 5 hours. In some embodiments, the dosage form may provide a mean Tmax of at least 5.5 hours. In some embodiments, the dosage form may provide a mean Tmax of at least 6 hours.
  • the stable dosage form can also provide a mean Tmax of about 4 hours to about 12 hours. For example, the stable dosage form can provide a mean Tmax of about 4 hours to about 10 hours. In some embodiments, the stable dosage form may provide a mean Tmax of about 4.5 hours to about 12 hours. In some embodiments, the dosage form may provide a mean Tmax of about 4.5 hours to about 10 hours. In some embodiments, the dosage form may provide a mean Tmax of about 5 hours to about 12 hours.
  • the dosage form may provide a mean Tmax of about 5 hours to about 10 hours. In some embodiments, the dosage form may provide a mean Tmax of about 4 hours to about 8 hours. In some embodiments, the dosage form may provide a mean Tmax of about 4.5 hours to about 8.5 hours. In some embodiments, the dosage form may provide a mean Tmax of about 5 hours to about 8 hours. In some embodiments, the dosage form may provide a mean Tmax of about 4 hours to about 9 hours. In some embodiments, the stable dosage form may provide a mean AUC0- ⁇ (plasma concentration of levomilnacipran over time) of about 500 to about 20,000 ng hr/mL.
  • AUC0- ⁇ plasma concentration of levomilnacipran over time
  • the stable dosage form may provide a mean AUC0- ⁇ (plasma concentration of levomilnacipran over time) of about 500 to about 15,000 ng hr/mL. In some embodiments, the stable dosage form may provide a mean AUC0- ⁇ (plasma concentration of levomilnacipran over time) of about 500 to about 10,000 ng hr/mL. In some embodiments, the stable dosage form may provide a mean AUC0- ⁇ (plasma concentration of levomilnacipran over time) of about 1000 to about 9000 ng.
  • the stable dosage form may provide a mean AUC0- ⁇ (plasma concentration of levomilnacipran over time) of about 500 to about 5,000 ng hr/mL. In some embodiments, the stable dosage form may provide a mean AUC0- ⁇ (plasma concentration of levomilnacipran over time) of about 500 to about 2500 ng hr/mL. In some embodiments, the dosage form may provide a mean AUC0- ⁇ of about 500 to about 2200 ng hr/mL. In some embodiments, the dosage form may provide a mean AUC0- ⁇ of about 700 to about 2500 ng hr/mL.
  • the dosage form may provide a mean AUC0- ⁇ of about 700 to about 2200 ng hr/mL. In some embodiments, the dosage form may provide a mean AUC0- Q O of about 800 to about 2200 ng hr/mL. In some embodiments, the dosage form may provide a mean AUC0- ⁇ of about 700 to about 2300 ng hr/mL. In some
  • the dosage form may provide a mean AUC0- ⁇ of about 1000 to about
  • the dosage form may provide a mean AUC0- ⁇ of about 1000 to about 1800 ng hr/mL. In some embodiments, the dosage form may provide a mean AUC0- ⁇ of about 1 100 to about 1800 ng hr/mL. In some embodiments, the dosage form may provide a mean AUC0- ⁇ of about 1200 to about 1700 ng hr/mL. In some embodiments, the dosage form may provide a mean AUC0- ⁇ of about 1300 to about 1700 ng hr/mL. In some embodiments, the dosage form may provide a mean AUCO-oo of about 1300 to about 1650 ng hr/mL.
  • the average maximum plasma concentration (Cmax) provided by the stable dosage forms can be modified (e.g., without substantially affecting the Tmax of the dosage form) by changing the strength of the dosage form.
  • the dosage form may provide a mean Cmax of less than about 200 ng/ml following administration (e.g., single administration) to a patient.
  • the dosage form may provide a mean Cmax of less than about 180 ng/ml.
  • the dosage form may provide a mean Cmax of less than about 170 ng/ml.
  • the dosage form may provide a mean Cmax of less than about 160 ng/ml.
  • the dosage form may provide a mean Cmax of less than about 150 ng/ml.
  • the dosage form may provide a mean Cmax of less than about 140 ng/ml. In some embodiments, the dosage form may provide a mean Cmax of less than about 130 ng/ml. In some embodiments, the dosage form may provide a mean Cmax of less than about 120 ng/ml. In some embodiments, the dosage form may provide a mean Cmax of less than about 1 10 ng/ml. In some embodiments, the dosage form may provide a mean Cmax of less than about 100 ng/ml. In some embodiments, the dosage form may provide a mean Cmax between about 20 and about 250 ng/mL. In some embodiments, the dosage form may provide a mean Cmax between about 20 and about 200 ng/mL.
  • the dosage form may provide a mean Cmax between about 20 and about 180 ng/mL. In some embodiments, the dosage form may provide a mean Cmax between about 30 and about 140 ng/mL. In some embodiments, the dosage form may provide a mean Cmax between about 40 and about 140 ng/mL. In some embodiments, the dosage form may provide a mean Cmax between about 20 and about 150 ng/mL.
  • the stable dosage forms have also been found, in some embodiments, to provide a mean half life (T1 ⁇ 2) of at least about 6 hours.
  • the dosage form may provide a mean T1 ⁇ 2 of at least about 7 hours.
  • the dosage form may provide a mean T1 ⁇ 2 of at least about 8 hours.
  • the dosage form may provide a mean T1 ⁇ 2 of at least about 9 hours.
  • the dosage form may provide a mean T1 ⁇ 2 of at least about 10 hours.
  • the dosage form may provide a mean T1 ⁇ 2 of at least about 1 1 hours.
  • the dosage form may provide a mean T1 ⁇ 2 of at least about 12 hours. In some embodiments, the dosage may provide a mean T1 ⁇ 2 of about 6 hours to about 24 hours. In some embodiments, the dosage may provide a mean T1 ⁇ 2 of about 6 hours to about 18 hours. In some embodiments, the dosage may provide a mean T1 ⁇ 2 of about 7 hours to about 18 hours. In some embodiments, the dosage may provide a mean T1 ⁇ 2 of about 8 hours to about 24 hours. In some embodiments, the dosage may provide a mean T1 ⁇ 2 of about 8 hours to about 18 hours.
  • the stable dosage form is a modified-release dosage form and provides a mean AUCo_ ⁇ between about 1000 and about 9000 ng hr/mL.
  • the stable dosage form is a modified-release dosage form and provides a mean Cmax between about 50 and about 350 ng/ml.
  • the stable dosage form is a modified-release dosage form and provides a mean Tmax between about 5 and 12 hours.
  • the stable dosage form is a modified-release dosage form and provides a mean T1 ⁇ 2 between about 9 hours and about 20 hours.
  • the stable dosage form is a modified-release dosage form and provides a mean AUCo_ ⁇ between about 1000 and about 9000 ng hr/mL, a mean Cmax between about 50 and about 350 ng/ml, a mean Tmax between about 5 and 12 hours, and a mean T1 ⁇ 2 between about 9 hours and about 20 hours.
  • the stable dosage form may provide a mean Cmax of less than about 200 ng/ml, a mean AUCo_ ⁇ of less than about 2500 ng hr/mL and a mean Tmax of at least about 4 hours.
  • the stable dosage form may provide a mean Cmax of less than about 180 ng/ml, a mean AUCo_ ⁇ of less than about 2500 ng hr/mL and a mean Tmax of at least about 4 hours.
  • the stable dosage form may provide a mean Cmax of less than about 160 ng/ml, a mean AUCo_ ⁇ of less than about 2500 ng hr/mL and a mean Tmax of at least about 4 hours. In some embodiments, the stable dosage form may provide a mean Cmax of less than about 150 ng/ml, a mean AUCo_ ⁇ of less than about 2500 ng hr/mL and a mean Tmax of at least about 4 hours.
  • the stable dosage form may provide a mean Cmax of less than about 140 ng/ml, a mean AUCo_ ⁇ of less than about 2500 ng hr/mL and a mean Tmax of at least about 4 hours.
  • the stable dosage form may provide a mean Cmax of less than about 140 ng/ml, a mean AUCo_ ⁇ of less than about 2200 ng hr/mL and a mean Tmax of at least about 4 hours.
  • the stable dosage form may provide a mean Cmax of less than about 180 ng/ml, a mean AUCo_ ⁇ of less than about 2200 ng hr/mL and a mean Tmax of at least about 5 hours.
  • the stable dosage form may provide a mean Cmax of less than about 180 ng/ml, a mean AUCo_ ⁇ of less than about 2200 ng hr/mL and a mean Tmax of at least about 6 hours.
  • the stable dosage form may provide a mean Cmax of about 10 to about 200 ng/ml, a mean AUCo_ ⁇ of about 500 to about 2500 ng hr/mL and a mean Tmax between about 4 to about 10 hours.
  • the stable dosage form may provide a mean Cmax of about 25 to about 175 ng/ml, a mean AUCo_ ⁇ of about 500 to about 2500 ng hr/mL and a mean Tmax between about 4 to about 10 hours.
  • the stable dosage form may provide a mean Cmax of about 30 to about 150 ng/ml, a mean AUCo_ ⁇ of about 500 to about 2500 ng hr/mL and a mean Tmax between about 4 to about 10 hours.
  • the stable dosage form may provide a mean Cmax of about 30 to about 120 ng/ml, a mean AUCo_ ⁇ of about 500 to about 2500 hr/mL and a mean Tmax between about 4 to about 10 hours. In some embodiments, the stable dosage form may provide a mean Cmax of about 10 to about 200 ng/ml, a mean AUCo_ ⁇ of about 600 to about 2200 ng hr/mL and a mean Tmax between about 4 to about 10 hours.
  • the stable dosage form may provide a mean Cmax of about 10 to about 200 ng/ml, a mean AUCo_ ⁇ of about 800 to about 2100 ng hr/mL and a mean Tmax between about 4 to about 10 hours.
  • the stable dosage form may provide a mean Cmax of about 10 to about 200 ng/ml, a mean AUCo_ ⁇ of about 900 to about 2100 ng hr/mL and a mean Tmax between about 4 to about 10 hours.
  • the stable dosage form may provide a mean Cmax of about 30 to about 150 ng/ml, a mean AUCo_ ⁇ of about 600 to about 2200 ng hr/mL and a mean Tmax between about 4 to about 10 hours.
  • the stable dosage form may provide a mean Cmax of about 30 to about 120 ng/ml, a mean AUCo_ ⁇ of about 600 to about 2200 ng hr/mL and a mean Tmax between about 4 to about 10 hours.
  • the stable dosage form may provide an in vivo plasma profile with a mean Cmax of about 10 to about 200 ng/ml, a mean AUCo_ ⁇ of about 500 to about 2500 ng hr/mL and a mean Tmax between about 4 to about 8 hours.
  • the stable dosage form may provide an in vivo plasma profile with a mean Cmax of about 10 to about 200 ng/ml, a mean AUCo_ ⁇ of about 500 to about 2500 ng hr/mL and a mean Tmax between about 5 to about 8 hours.
  • the stable dosage form may provide an in vivo plasma profile with a mean Cmax of about 25 to about 175 ng/ml, a mean AUCo_ ⁇ of about 600 to about 2200 ng hr/mL ng hr/mL and a mean Tmax between about 4 to about 9 hours.
  • the stable dosage form may provide an in vivo plasma profile with a mean Cmax of about 30 to about 150 ng/ml, a mean AUCo_ ⁇ of about 800 to about 2100 ng hr/mL ng hr/mL and a mean Tmax between about 4 to about 9 hours.
  • a dosage form is provided, wherein the dosage form may provide an in vivo plasma profile with a mean Cmax of less than about 125 ng/ml, a mean AUCo- ⁇ of less than about 1000 to about 2200 ng hr/mL and a mean Tmax of at least about 4 hours.
  • the present invention also provides methods for treating a disease, disorder or condition that can be managed by inhibition ⁇ e.g., double inhibition and/or selective inhibition) of 5-HT and NE reuptake, for example, anxiety disorders or depression ⁇ e.g., major depressive disorder (MDD)) in a mammal ⁇ e.g., human) by administering the stable dosage form to a patient in need thereof.
  • a disease, disorder or condition that can be managed by inhibition ⁇ e.g., double inhibition and/or selective inhibition) of 5-HT and NE reuptake, for example, anxiety disorders or depression ⁇ e.g., major depressive disorder (MDD)) in a mammal ⁇ e.g., human) by administering the stable dosage form to a patient in need thereof.
  • MDD major depressive disorder
  • a method for treating or preventing depression ⁇ e.g., atypical depression or MDD), anxiety ⁇ e.g., generalized anxiety disorder) or fatigue associated with depression or anxiety in a patient in need thereof by administering the stable dosage form of levomilnacipran to said patient.
  • a method is provided for treating or preventing major depressive disorder (MDD) ⁇ e.g., acute MDD or atypical MDD) in a patient in need thereof by administering the stable dosage form of levomilnacipran to said patient.
  • MDD major depressive disorder
  • a method for treating or preventing MDD with unresolved, concomitant or accompanying fatigue in a patient in need thereof by administering the stable dosage form of levomilnacipran to said patient.
  • the stable dosage form of levomilnacipran is used to treat or prevent relapse of MDD in a patient in need thereof by administering the dosage form to said patient.
  • the stable dosage form is used to treat or prevent fatigue ⁇ e.g., fatigue associated with MDD or other form of depression) in a patient in need thereof by administering the dosage form to said patient.
  • the stable dosage form is used to treat or prevent sexual dysfunction ⁇ e.g., erectile dysfunction) in a patient in need thereof by administering the dosage form to said patient.
  • the stable dosage form is used to treat or prevent pain associated with depression ⁇ e.g., MDD) in a patient in need thereof by administering the dosage form to said patient.
  • the stable dosage form of the present invention is used to treat or prevent melancholia, dysthymia, somnolence, cognitive impairment, sleep disorders and/or hyperlipidemia associated (or concomitant) with depression (e.g., MDD) in a patient in need thereof by administering the stable dosage form to said patient.
  • a method for treating or preventing neuropathic pain (e.g., diabetic polyneuropathic pain (DPNP)) in a patient in need thereof, wherein the method comprises administering an effective amount of the stable dosage form of levomilnacipran to the patient.
  • neuropathic pain e.g., diabetic polyneuropathic pain (DPNP)
  • DPNP diabetic polyneuropathic pain
  • a method for obtaining a flattened drug plasma concentration to time profile thereby affording a tighter plasma therapeutic range control than can be obtained with multiple daily dosing.
  • a method is provided for eliminating the sharp peaks and troughs in blood plasma drug levels induced by multiple daily dosing with conventional immediate release formulations of levomilnacipran.
  • the plasma levels of levomilnacipran rise after administration of the stable dosage forms of this invention for several hours and then begin to fall through a protracted, substantially linear decrease from the peak plasma level for the remainder of an approximately twenty-four hour period, maintaining at least a threshold therapeutic level of levomilnacipran during the entire period.
  • Beads of levomilnacipran were prepared by preheating sugar spheres (approximately 30-35 mesh) and layering the preheated sugar spheres with a drug layer solution for about 3.5 hours via a Wurster process to form drug-loaded beads.
  • the drug layer solution included levomilnacipran, Povidone K30, talc and a dehydrated alcohol.
  • the drug-loaded beads were dried in the fluid bed for about 30 minutes and sieved to yield immediate-release levomilnacipran beads (approx. 540 mg/g) which comprised approximately the concentrations of components shown in Table 4:
  • the levomilnacipran beads were then preheated and coated with a dispersion solution via a Wurster process.
  • the dispersion solution comprised ethyl cellulose N22, triethyl citrate, talc and a dehydrated alcohol.
  • the coated beads were carefully cured in the fluid bed and screened to yield sustained release beads of levomilnacipran (approx. 460 mg/g) prior to filling into capsules.
  • the sustained release levomilnacipran beads comprised approximately the concentrations of components shown in Table 5: Table 5
  • Example 2 Stability of the Dosage Form Prepared in Example 1
  • the stability of the dosage form of levomilnacipran prepared in Example 1 was assessed following storage of the dosage form in two different types of capsules (namely, hard gelatin capsules and HPMC capsules) for three months at 40°C and 75% relative humidity (RH).
  • Table 6 shows the approximate concentrations of impurities that were found within the hard gelatin capsules of the stable dosage form of levomilnacipran following three months of storage.
  • Table 7 shows the approximate concentrations of impurities that were found within HPMC capsules of the stable dosage form of levomilnacipran.
  • Example 3 Dissolution Rates of Dosage Form Prepared in Example 1
  • the dissolution rates of the stable dosage form of levomilnacipran prepared in Example 1 was evaluated in 1000 mL of deionized water at 37°C using USP apparatus II at 75 rpm. Quantification of levomilnacipran was determined using HPLC with a UV detector at a wavelength of 220 nm.
  • Example 1 The dissolution profile of the stable dosage form prepared in Example 1 (and loaded into an HPMC capsule containing no desiccant) is shown in Figure 1 and in Table 8.
  • the dissolution profile of the stable dosage form prepared in Example 1 was also determined after storing the dosage form for one, two and three months at 40°C and 75% relative humidity (RH), wherein the dosage form was loaded into HPMC capsules (containing 1 gram or no desiccant), as is shown in Table 8 and in Figures 1-5.
  • Figure 1 shows the dissolution rate for the stable dosage form of levomilnacipran after no storage, wherein the dosage form is loaded into an HPMC capsule that contains no desiccant.
  • Figure 2 shows the dissolution rate for the stable dosage form of levomilnacipran after 1 month of storage at 40°C and 75% RH, wherein the dosage form is loaded into an HPMC capsule that contains no desiccant.
  • Figure 3 shows the dissolution rate for the stable dosage form of levomilnacipran after 2 months of storage at 40°C and 75% RH, wherein the dosage form is loaded into an HPMC capsule that contains no desiccant.
  • Figure 4 shows the dissolution rate for the stable dosage form of levomilnacipran after 3 months of storage at 40°C and 75% RH, wherein the dosage form is loaded into an HPMC capsule that contains no desiccant.
  • Figure 5 shows the dissolution rate for the stable dosage form of levomilnacipran after 3 months of storage at 40°C and 75% RH, wherein the dosage form is loaded into an HPMC capsule that contains 1 gram of desiccant.
  • a sample of an active ingredient comprising at least 98% by weight of levomilnacipran hydrochloride was loaded onto a deep aluminum holder and exposed to CuKa radiation (40kV x 40 mA) in a wide-angle bench-top X-ray diffractometer (Model D8, Bruker AXS Inc., Madison WI).
  • the instrument was operated in the step-scan mode in increments of 0.05°2 ⁇ .
  • the angular range was 5 to 40°2 ⁇ , and the scan rate was 0.15°29/min.
  • the data collection and analyses were performed with commercially available software.
  • Example 5 - X-Ray Powder Diffractometry (XRD) Analysis of the Immediate- Release Levomilnacipran Beads Prepared in Example 1
  • XRD X-Ray Powder Diffractometry
  • Peak positions for the XRD pattern in Figure 7 are provided in Table 2.
  • Example 6 X-Ray Powder Diffractometry (XRD) Analysis of the Sustained-Release Dosage Form Prepared in Example 1
  • Example 1 A small amount of the sustained-release dosage form prepared in Example 1 was loaded on a deep aluminum holder and exposed to CuKa radiation (40kV x 40 mA) in a wide-angle bench-top X-ray diffractometer (Model D8, Bruker AXS Inc., Madison WI). The instrument was operated in a step-scan mode in increments of 0.05°2 ⁇ . The angular range was 5 to 40°2 ⁇ , and the scan rate was 0.15°29/min. Data collection and analyses were performed with commercially available software (specifically, DIFFRACplus XRD Commander, Bruker-AXS GmbH; and JADE, Materials Data, Inc.). The XRD pattern for the stable dosage form of levomilnacipran is shown in
  • the stable dosage forms of levomilnacipran of the present invention can be administered to human patients in the form of capsules that contain 50 mg of
  • the capsules may contain microgranules that are coated with about 7.5 wt.% of ethyl cellulose (EC) ("dosage form 1"), about 10 wt.% EC ("dosage form 2”) and about 12.5 wt.% EC ("dosage form 3").
  • EC ethyl cellulose
  • Dosage forms 1-3 can be administered to patients after a fasting period of at least about 10 hours.
  • Blood samples can be collected from each patient before administration and at several time points after administration (e.g., at 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 10 hours, 12 hours, 24 hours, 48 hours and 72 hours).
  • Plasma samples from each patient can be assayed for levomilnacipran quantification using a validated on-line extraction method (Turbulent Flow
  • PK pharmacokinetic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/US2011/021315 2010-01-14 2011-01-14 Stable dosage forms of levomilnacipran WO2011088331A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2012549117A JP2013517290A (ja) 2010-01-14 2011-01-14 レボミルナシプランの安定した剤形
EP11733447.4A EP2536688A4 (de) 2010-01-14 2011-01-14 Stabile dosierungsformen von levomilnacipran
CA2790933A CA2790933A1 (en) 2010-01-14 2011-01-14 Stable dosage forms of levomilnacipran

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29489810P 2010-01-14 2010-01-14
US61/294,898 2010-01-14
US12/941,293 US8865937B2 (en) 2009-11-06 2010-11-08 Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide
US12/941,293 2010-11-08

Publications (1)

Publication Number Publication Date
WO2011088331A1 true WO2011088331A1 (en) 2011-07-21

Family

ID=44304671

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/021315 WO2011088331A1 (en) 2010-01-14 2011-01-14 Stable dosage forms of levomilnacipran

Country Status (4)

Country Link
EP (1) EP2536688A4 (de)
JP (1) JP2013517290A (de)
CA (1) CA2790933A1 (de)
WO (1) WO2011088331A1 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013014263A1 (fr) * 2011-07-28 2013-01-31 Pierre Fabre Medicament Medicament a base de levomilnacipran pour la rehabilitation fonctionnelle apres accident neurologique aigu
CN110711185A (zh) * 2018-07-11 2020-01-21 北京万全德众医药生物技术有限公司 左旋米那普仑缓释胶囊

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040034101A1 (en) * 2001-11-05 2004-02-19 Cypress Bioscience, Inc. Treatment and prevention of depression secondary to pain (DSP)
US20040259953A1 (en) * 2003-02-14 2004-12-23 Jean Deregnaucourt Use of the (1S,2R) enantiomer of milnacipran for the preparation of a drug
US20060154938A1 (en) * 2002-12-27 2006-07-13 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2752732B1 (fr) * 1996-08-28 1998-11-20 Pf Medicament Forme galenique a liberation prolongee de milnacipran
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
JP5036029B2 (ja) * 2005-06-10 2012-09-26 旭化成ファーマ株式会社 安定化されたミルナシプラン製剤
JP2008273867A (ja) * 2007-04-27 2008-11-13 Asahi Kasei Pharma Kk 経粘膜投与用製剤
EP2110129A1 (de) * 2008-04-18 2009-10-21 Pierre Fabre Medicament Verwendung von Enanotimer (1S, 2R) Milnacipran-Hydrochlorid zur präventiven Behandlung von Suizidverhalten bei depressiven Patienten
WO2010129689A1 (en) * 2009-05-05 2010-11-11 Forest Laboratories Holdings Limited Milnacipran formulations
EP2496079A4 (de) * 2009-11-06 2014-05-14 Pierre Fabre Médicament Sas Neue kristalline formen von (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenylcyclopropancarboxamid

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040034101A1 (en) * 2001-11-05 2004-02-19 Cypress Bioscience, Inc. Treatment and prevention of depression secondary to pain (DSP)
US20060154938A1 (en) * 2002-12-27 2006-07-13 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
US20040259953A1 (en) * 2003-02-14 2004-12-23 Jean Deregnaucourt Use of the (1S,2R) enantiomer of milnacipran for the preparation of a drug

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2536688A4 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013014263A1 (fr) * 2011-07-28 2013-01-31 Pierre Fabre Medicament Medicament a base de levomilnacipran pour la rehabilitation fonctionnelle apres accident neurologique aigu
FR2978350A1 (fr) * 2011-07-28 2013-02-01 Pf Medicament Medicament a base de levomilnacipran pour la rehabilitation fonctionnelle apres accident neurologique aigu
CN110711185A (zh) * 2018-07-11 2020-01-21 北京万全德众医药生物技术有限公司 左旋米那普仑缓释胶囊

Also Published As

Publication number Publication date
JP2013517290A (ja) 2013-05-16
CA2790933A1 (en) 2011-07-21
EP2536688A1 (de) 2012-12-26
EP2536688A4 (de) 2014-04-02

Similar Documents

Publication Publication Date Title
US20180028476A1 (en) Stable dosage forms of levomilnacipran
AU737121B2 (en) Tramadol multiple unit formulations
EP2205279B1 (de) Pharmazeutische kombination aus aliskiren und valsartan
WO2008020286A2 (en) Pharmaceutical compositions of duloxetine
KR20090029830A (ko) 소장 내에서 활성성분의 방출이 제어되는 경구투여용 약제학적 조제물 및 그의 제조방법
CA2627198A1 (en) Methylphenidate extended release therapeutic drug delivery system
EP2968177A1 (de) Topiramat-kapseln mit verlängerter freisetzung
EP2536688A1 (de) Stabile dosierungsformen von levomilnacipran
US20200253901A1 (en) Stable dosage forms of levomilnacipran
US20110130434A1 (en) Modified release ramipril compositions and uses thereof
AU2016255302B2 (en) Rivastigmine-containing sustained-release pharmaceutical composition
AU2006247357B2 (en) Morphine sulfate formulations
US20120082718A1 (en) Morphine Formulations
NZ532876A (en) Methods and compositions for use of (S)-bisoprolol
JP2013526601A (ja) プラミペキソールの徐放性製剤
ZA200403764B (en) Methods and compositions for use of (S)-bisoprolol.
AU2002348878A1 (en) Methods and compositions for use of (S)-bisoprolol

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2012549117

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011733447

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2790933

Country of ref document: CA